Clinical studies have shown that MT1A and MT2A levels are upregulated in subcutaneous and visceral adipose tissues of patients with obesity or type 2 diabetes [49,50], implying that increased expression of MTs in human adipose tissues may be either a factor contributing to the development of obesity or a consequence of obesity. Here, MT2A is linked to type 2 diabetes mellitus.